These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18676739)

  • 1. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer.
    De Toni EN; Thieme SE; Herbst A; Behrens A; Stieber P; Jung A; Blum H; Göke B; Kolligs FT
    Clin Cancer Res; 2008 Aug; 14(15):4713-8. PubMed ID: 18676739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
    Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
    J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
    Shan BE; Wang MX; Li RQ
    Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
    Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
    Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin is expressed in colon carcinoma cells.
    Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
    Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
    Chamoux E; Houde N; L'Eriger K; Roux S
    J Cell Physiol; 2008 Aug; 216(2):536-42. PubMed ID: 18338379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
    Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
    Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
    Sandra F; Hendarmin L; Nakamura S
    Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
    Holen I; Croucher PI; Hamdy FC; Eaton CL
    Cancer Res; 2002 Mar; 62(6):1619-23. PubMed ID: 11912131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and functional activity of osteoprotegerin in human malignant gliomas.
    Naumann U; Wick W; Beschorner R; Meyermann R; Weller M
    Acta Neuropathol; 2004 Jan; 107(1):17-22. PubMed ID: 14504888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand.
    Yoshida T; Maoka T; Das SK; Kanazawa K; Horinaka M; Wakada M; Satomi Y; Nishino H; Sakai T
    Mol Cancer Res; 2007 Jun; 5(6):615-25. PubMed ID: 17579120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
    Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
    Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
    Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells.
    Kapoor P; Suva LJ; Welch DR; Donahue HJ
    J Cell Biochem; 2008 Jan; 103(1):30-41. PubMed ID: 17471510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling.
    Kojima T; Shimazui T; Hinotsu S; Joraku A; Oikawa T; Kawai K; Horie R; Suzuki H; Nagashima R; Yoshikawa K; Michiue T; Asashima M; Akaza H; Uchida K
    Oncogene; 2009 Jan; 28(2):297-305. PubMed ID: 18931698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.